G - Index
In this guide
In this guideOn this page
Skip the menu of subheadings on this page.|
Subject: GADD45a GFP ‘Green Screen’ assay |
Year |
Page |
|
COM Discussion of |
2010 |
42 |
|
Subject: Gallates (anti-oxidants in food) |
Year |
Page |
|
COM Discussion of |
1992 |
37 |
|
Subject: Gellan gum |
Year |
Page |
|
COT Evaluation of |
1993 |
13 |
|
Subject: Genetically modified |
Year |
Page |
|
Potatoes genetically modified to produce Galanthus nivalis Lectin |
1999 |
34 |
|
Subject: Genetic susceptibility to cancer |
Year |
Page |
|
COC/COM Joint Symposium on |
1998 |
33 |
|
Joint COC/COM symposium on genetic susceptibility to cancer |
1998 |
35 |
|
COC scoping discussion on, |
2000 |
110 |
|
Subject: Genomics and proteomics in toxicology, Joint meeting of COT/COC/COM on |
Year |
Page |
|
assessing their current and future potential as tools in regulatory risk assessments. |
2001
|
24, 109, 143 |
|
use of genomics and proteomics in toxicology |
2002 |
14 |
|
Subject: Genotoxic Consequences of Exposure to Mixtures of Food Derived Chemical Carcinogens |
Year |
Page |
|
COM review of FSA funded research on |
2012 |
39 |
|
Subject: Genotoxic alkylating agents |
Year |
Page |
|
Thresholds for |
2006 |
237 |
|
Subject: Genotoxic carcinogens |
Year |
Page |
|
and DNA repair at low doses |
2004 |
136, 176 |
|
Acute T25 – possible approach to potency ranking of single exposure |
2006 |
279 |
|
The occurrence of “U” shaped dose dose-response curves |
2003 |
196 |
|
European Food Safety Authority (EFSA) Advice to- chemicals that are genotoxic and carcinogenic |
2005 |
141 |
|
Genotoxicity Testing of Impurities |
2011 |
44 |
|
Interim Guidance on a Strategy for Genotoxicity Testing and Assessment of Impurities |
2012 |
35 |
|
Subject: Genotoxicity data |
Year |
Page |
|
Interpretation of, two-day 2019 workshop on |
2020 |
48 |
|
Subject: Genotoxicity, evidence for |
Year |
Page |
|
Genotoxicity testing and mutagenic hazard assessment of chemical substances. Consultation on a strategy for |
2010 |
48 |
|
consolidated summary of discussions |
2017 |
42 |
|
Subject: Genotoxicity of Nanomaterials |
Year |
Page |
|
A COM statement is currently being drafted |
2011 |
45 |
|
in vitro genotoxicity testing of nanomaterials |
2012 |
36 |
|
Subject: Genotoxicity of water and wastewater |
Year |
Page |
|
ISO Water quality standard: Determination of the genotoxicity of water and waste water using the umu test |
1997 |
69 |
|
Subject: Genotype and environment interaction on susceptibility to cancer |
Year |
Page |
|
COC review of |
2001 |
121 |
|
The investigation of interaction between genotype and chemicals in the environment on the induction of cancer |
2002 |
132 |
|
Genotypes and chemicals in the environment on the induction of cancer in risk assessment. Interaction between |
2010 |
59 |
|
Subject: Germ cell mutagenesis |
Year |
Page |
|
investigating germ cell mutagenesis, the germ cell genome, meiosis and mutagenesis, the paternal age effect and aneuploidy in germ cells |
2015 |
38 |
|
adverse outcome pathways |
2016 |
34 |
|
consolidated summary of discussions |
2017 |
43 |
|
Strategy for investigating germ cell mutagens |
2003 |
138 |
|
Germ cell mutagens, COM guidance on testing |
2021 |
53 |
|
Subject: Ginger |
Year |
Page |
|
ongoing work on the COT contribution to the SACN risk assessment on nutrition and, ginger |
2021 |
33 |
|
Subject: Glucosamine and hepatotoxicity |
Year |
Page |
|
a very small number of individual case reports linking glucosamine and hepatitis |
2008 |
20 |
|
case reports linking glucosamine and hepatitis |
2009 |
15, 38 |
|
Subject: Gluten – timing of introduction into the infant diet |
Year |
Page |
|
and subsequent risk of developing coeliac disease or type 1 diabetes mellitus (T1DM) |
2010 |
27 |
|
Further discussions on subsequent risk of developing coeliac disease or type 1 diabetes mellitus (T1DM) |
2011 |
11 |
|
Subject: Guidance statement on the human health significance of chemical induced mutagenicity |
Year |
Page |
|
joint COC, COM and COT workshop on ‘Whether epigenetics should be used in chemical risk assessment’ |
2017 |
55 |
|
information on chemically induced mutagenesis relevant to human health to the informed lay reader. |
2013 |
45, 59 |
|
Subject: Guidance statements, COC |
Year |
Page |
|
Mode of Action, Human Relevance Framework and Margin of Exposure |
2011 |
58 |
|
overarching statement G1, a statement on risk characterisation methods for carcinogens |
2012 |
48 |
|
Overarching strategy (GO1) |
2019 |
53 |
|
Guidance statement update |
2020 |
65 |
|
Guidance statement update on the use of biomarkers in carcinogenic risk assessment (G04) |
2018
|
52
|
|
Hazard identification and characterisation: conduct and interpretation of animal carcinogenicity studies (G03), update of |
2021 |
80 |
|
Guidance statement update |
2018 |
52 |
|
Defining a point of departure and potency estimates in carcinogenic dose response (G05) |
2018 |
52 |
|
Guidance statement update |
2018 |
52 |
|
Further discussion papers on |
2019 |
53 |
|
Risk characterisation methods (G06) |
2018 |
52 |
|
Risk characterisation methods (G06) update of |
2021 |
80 |
|
Alternatives to the 2-year bioassay (G07) |
2018 |
52 |
|
Combined exposure to chemical carcinogens (GO8) |
2019 |
54 |
|
Less than lifetime exposure (GO9) |
2019 |
54 |
|
Subject: Guidance statements, COM |
Year |
Page |
|
Guidance on use of (Q)SAR models to predict genotoxicity, evaluation of in vivo genotoxicity |
2018 |
40 |
|
Guidance on Mutagenic Hazard Assessment and a Strategy for Genotoxicity Testing of Chemicals with Inadequate Genotoxicity Data |
2011 |
43 |
|
Guidance on the use of (Q)SAR models to predict genotoxicity |
2018 |
40 |
|
Guidance series, COM update of |
2019 |
34 |
|
Guidance series, COM update of |
2020 |
47 |
|
Guidance series, COM update of |
2021 |
53 |
|
Guidance on assessment strategies and genotoxicity tests |
2010 |
41 |
|
ICH guidelines: Genotoxicity: A standard battery for genotoxicity testing of pharmaceuticals (S2B) and consideration of the mouse lymphoma assay |
1997 |
75 |
|
Germ cell mutagens, guidance on |
2021 |
53 |
|
3D models, guidance on |
2021 |
53 |
|
Testing strategies for nanomaterials, guidance on |
2021 |
54 |
|
Testing strategies for impurities, update on guidance |
2021 |
54 |
|
Use of QSAR models, guidance on |
2021 |
54 |
|
Subject: Gut microbiome |
Year |
Page |
|
effects of xenobiotics on |
2019 |
15 |
|
statement on the effect of xenobiotics on the gut microbiome and the effect the gut microbiome on xenobiotics with reference to chemical risk assessment |
2020 |
11 |